BioSpace News Archive

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that John Bencich, Achieve’s Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M-Vest and Maxim Group.

- Patients treated with mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints compared to placebo - LUCENT-1 is the first and only Phase 3 study of an anti-IL-23p19 monoclonal antibody to demonstrate reduced bowel urgency in moderate to severe ulcerative colitis - Safety results in this study were consistent with that of the previous mirikizumab study in ulcerative colitis and studies with the anti-IL-23p19 antibody class

Data show more than 50 percent of adults with active PsA achieved complete skin clearance (PASI 100) and more than 70 percent achieved at least 20 percent improvement in joint symptoms (ACR 20)

Global Blood Therapeutics, Inc. announced it has entered into an agreement with Sanofi S.A. to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease : one that pursues a novel anti-sickling mechanism and another that leverages a new approach to reduce inflammation and oxidative stress.

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced it has completed enrollment for its Phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.

Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduce length of hospital stay.

FibroGen, Inc. announced the initiation of LELANTOS-2, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with ambulatory Duchenne muscular dystrophy.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced it will host a Virtual Rare Disease Forum on Tuesday, March 23rd, 2021 from 1:00pm to 3:00pm ET.

Medicago, a biopharmaceutical company headquartered in Quebec City and GlaxoSmithKline, are pleased to announce the start of Phase 3 clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase 2/3 study.

Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody , chief executive officer, will present at the Virtual KeyBanc Life Sciences & MedTech Investor Forum Tues., March 23 at approximately 2 p.m., ET .